Reduced thromboembolic events with DN-101 (high-dose calcitriol) treatment of androgen-independent prostate cancer: Hypothesis for a new class of anticoagulants
Venner P, Ryan C, Petrylak D, Chatta G, Ruether J, Chi K, Curd J, Beer T. Reduced thromboembolic events with DN-101 (high-dose calcitriol) treatment of androgen-independent prostate cancer: Hypothesis for a new class of anticoagulants. Journal Of Clinical Oncology 2006, 24: 4505-4505. DOI: 10.1200/jco.2006.24.18_suppl.4505.Peer-Reviewed Original ResearchAndrogen-independent prostate cancerSerious adverse eventsThromboembolic eventsDN-101Prostate cancerExact testMetastatic androgen-independent prostate cancerIncidence of TEPlacebo-controlled studyVDR knockout miceEffects of calcitriolFisher's exact testDocetaxel regimenPlacebo groupAdvanced malignanciesAdverse eventsVitamin DBaseline useEfficacy resultsGrade 3Study groupNatural anticoagulantsOral formulationKnockout micePatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply